Wednesday, April 30, 2025 1:50:24 PM
iclight,
You asked me about share price and my investment and about long investors’ inclination to “hold,” but your post was deleted—I wanted to answer your question!
Thanks for asking 😶 …
I’ve been buying since 2022 at various levels—probably around $1.00 on average, but I don’t focus on that—it’s entirely irrelevant to my investment thesis for this particular biotech. I didn’t invest for short-term penny gains at the initial clinical development stage or ‘pre-commercial’ stage. I’m here for the vast prospective value that I anticipate will materialize as catalysts unfold and the company moves toward commercialization across multiple markets.
It is difficult to measure and forecast a numerical value of DC platforms. In my view, checkpoint blockade technology can help us apply a reasonable measure to enlighten how vast the value may be…
🔑 In others words, if someone asks “how much” a DC platform is worth, a reasonably grounded response might be: “How much is checkpoint blockade worth?”
If DC tech drives the immune response; overcomes resistance; unlocks efficacy, then it’s fair to ask—what’s that worth? Same as checkpoint inhibitors… or perhaps more.
DCVax-L was the first of NWBO’s technologies to complete PIII, and the Roswell platform has reached PII—the most noteworthy aspect today is the combo efficacy data that’s beginning to emerge, especially since checkpoint inhibitors (one of the combo agents) are already part of the SoC for some cancers and checkpoint inhibitors are already commercialized worldwide! 🌏️
DCVax-L, DCVax-D, and the Roswell DC product are patent-fortified cell-based platform technologies that are increasingly validated by the clinical data that continue to accumulate each day…
⭐️Combo is King!⭐️
Also irrelevant—baseless rumors and share price manipulators.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176130558
BP appears to be recognizing the vast potential of dendritic cell (DC) technology—born from a Nobel Prize-winning discovery—especially in combo with checkpoint inhibitors, which also stem from Nobel-winning science.
The recent green light for the expansion of the pembrolizumab combo research at Roswell has brought some focus back on the Merck dot connecting (or other companies that make checkpoint inhibitors)…
Grant-funded trials are peer-reviewed, and the reviewers generally approve funding/expansion based on preliminary data. Notably, the PII trials at Roswell Park have been approved to expand in scope.. and look who joked on X about the overly-rigorous peer-review process for grant funding—the principal investigator of one of the Roswell trials!
So, it looks like the grant peer reviewers have been watching the PII trials closely 🤔 …
Since the peer-reviewed Roswell trials include pembrolizumab, we are a bit curious about Merck’s interest and awareness of DC platforms and how emerging interim data might lead to new combo possibilities…
These three scientists have coauthored several publications on dendritic cell vaccines, and all three were recently recruited by Merck in 2023 and 2024:
☑️ Juraj Adamik
☑️ Paul Munson
☑️ Lisa H. Butterfield
https://acir.org/weekly-digests/2023/november/metabolic-characteristics-of-dc-vaccines-define-therapy-responses
https://www.nature.com/articles/s41467-023-42881-4
https://www.nature.com/articles/s41467-022-32849-1
https://www.sciencedirect.com/science/article/abs/pii/B9780128239018000030
Adamik and Butterfield are coauthors of this publication along with several University of Pittsburgh researchers:
https://rupress.org/jem/article/217/7/e20191369/151736/Impact-of-checkpoint-blockade-on-cancer-vaccine
Pawel Kalinski of Roswell Park and Lisa Butterfield are coauthors on this 2021 publication:
https://jitc.bmj.com/content/9/11/e003675
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456
Roswell DC Platform:
In addition to the expansion referenced above in a recent NWBO SEC filing, the other PII also had a recent change…
⭐️ Trial Update Published 27 Feb 2025:
https://clinicaltrials.gov/study/NCT04348747?a=29&b=30
The trial scope and title were expanded to include hormone receptor-positive (HR+) breast cancer, the most common subtype.
☑️ Increased Patient Eligibility: A broader population now qualifies.
☑️ Scientific Implications: Potential efficacy beyond TNBC and HER2+ cases, possibly due to shared immune mechanisms.
☑️ Regulatory & Market Impact: Broader applicability could enhance approval prospects and market potential.
☑️ Trial Design Adjustments: May involve new stratification to account for differences in tumor biology.
Dr. Kabraji recently mentioned and cited the pembrolizumab + DC vaccine trial in a passing comment on X in response to someone on another topic, but I found his comment insightful considering the date of his X reply post and the context of the recent trial updates…his post was just weeks before he became the principal investigator of that trial…
You asked me about share price and my investment and about long investors’ inclination to “hold,” but your post was deleted—I wanted to answer your question!
Thanks for asking 😶 …
I’ve been buying since 2022 at various levels—probably around $1.00 on average, but I don’t focus on that—it’s entirely irrelevant to my investment thesis for this particular biotech. I didn’t invest for short-term penny gains at the initial clinical development stage or ‘pre-commercial’ stage. I’m here for the vast prospective value that I anticipate will materialize as catalysts unfold and the company moves toward commercialization across multiple markets.
It is difficult to measure and forecast a numerical value of DC platforms. In my view, checkpoint blockade technology can help us apply a reasonable measure to enlighten how vast the value may be…
🔑 In others words, if someone asks “how much” a DC platform is worth, a reasonably grounded response might be: “How much is checkpoint blockade worth?”
If DC tech drives the immune response; overcomes resistance; unlocks efficacy, then it’s fair to ask—what’s that worth? Same as checkpoint inhibitors… or perhaps more.
DCVax-L was the first of NWBO’s technologies to complete PIII, and the Roswell platform has reached PII—the most noteworthy aspect today is the combo efficacy data that’s beginning to emerge, especially since checkpoint inhibitors (one of the combo agents) are already part of the SoC for some cancers and checkpoint inhibitors are already commercialized worldwide! 🌏️
DCVax-L, DCVax-D, and the Roswell DC product are patent-fortified cell-based platform technologies that are increasingly validated by the clinical data that continue to accumulate each day…
⭐️Combo is King!⭐️
Also irrelevant—baseless rumors and share price manipulators.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176130558
BP appears to be recognizing the vast potential of dendritic cell (DC) technology—born from a Nobel Prize-winning discovery—especially in combo with checkpoint inhibitors, which also stem from Nobel-winning science.
The recent green light for the expansion of the pembrolizumab combo research at Roswell has brought some focus back on the Merck dot connecting (or other companies that make checkpoint inhibitors)…
Grant-funded trials are peer-reviewed, and the reviewers generally approve funding/expansion based on preliminary data. Notably, the PII trials at Roswell Park have been approved to expand in scope.. and look who joked on X about the overly-rigorous peer-review process for grant funding—the principal investigator of one of the Roswell trials!
Reviewers asking for prelim data when the grant mechanism says “prelim data not required” pic.twitter.com/qrBBnIvedt
— Sheheryar Kabraji (@SKabrajiMD) March 5, 2025
So, it looks like the grant peer reviewers have been watching the PII trials closely 🤔 …
Since the peer-reviewed Roswell trials include pembrolizumab, we are a bit curious about Merck’s interest and awareness of DC platforms and how emerging interim data might lead to new combo possibilities…
These three scientists have coauthored several publications on dendritic cell vaccines, and all three were recently recruited by Merck in 2023 and 2024:
☑️ Juraj Adamik
☑️ Paul Munson
☑️ Lisa H. Butterfield
https://acir.org/weekly-digests/2023/november/metabolic-characteristics-of-dc-vaccines-define-therapy-responses
https://www.nature.com/articles/s41467-023-42881-4
https://www.nature.com/articles/s41467-022-32849-1
https://www.sciencedirect.com/science/article/abs/pii/B9780128239018000030
Adamik and Butterfield are coauthors of this publication along with several University of Pittsburgh researchers:
https://rupress.org/jem/article/217/7/e20191369/151736/Impact-of-checkpoint-blockade-on-cancer-vaccine
Pawel Kalinski of Roswell Park and Lisa Butterfield are coauthors on this 2021 publication:
https://jitc.bmj.com/content/9/11/e003675
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456
Roswell DC Platform:
In addition to the expansion referenced above in a recent NWBO SEC filing, the other PII also had a recent change…
⭐️ Trial Update Published 27 Feb 2025:
https://clinicaltrials.gov/study/NCT04348747?a=29&b=30
The trial scope and title were expanded to include hormone receptor-positive (HR+) breast cancer, the most common subtype.
☑️ Increased Patient Eligibility: A broader population now qualifies.
☑️ Scientific Implications: Potential efficacy beyond TNBC and HER2+ cases, possibly due to shared immune mechanisms.
☑️ Regulatory & Market Impact: Broader applicability could enhance approval prospects and market potential.
☑️ Trial Design Adjustments: May involve new stratification to account for differences in tumor biology.
Dr. Kabraji recently mentioned and cited the pembrolizumab + DC vaccine trial in a passing comment on X in response to someone on another topic, but I found his comment insightful considering the date of his X reply post and the context of the recent trial updates…his post was just weeks before he became the principal investigator of that trial…
Ongoing clinical trial @RoswellPark led by @gandhi_shipra for pts with asymptomatic #bcsm brain mets has changed our practice. Can’t change therapy unless these patients are entered into trial but entry requires screening brain MRI https://t.co/3QlS0DgVgz
— Sheheryar Kabraji (@SKabrajiMD) February 1, 2025
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
